| Literature DB >> 24782827 |
Anders Rehfeld1, Mireya Plass2, Kristina Døssing1, Ulrich Knigge3, Andreas Kjær4, Anders Krogh2, Lennart Friis-Hansen1.
Abstract
The tumorigenesis of small intestinal neuroendocrine tumors (SI-NETs) is poorly understood. Recent studies have associated alternative polyadenylation (APA) with proliferation, cell transformation, and cancer. Polyadenylation is the process in which the pre-messenger RNA is cleaved at a polyA site and a polyA tail is added. Genes with two or more polyA sites can undergo APA. This produces two or more distinct mRNA isoforms with different 3' untranslated regions. Additionally, APA can also produce mRNAs containing different 3'-terminal coding regions. Therefore, APA alters both the repertoire and the expression level of proteins. Here, we used high-throughput sequencing data to map polyA sites and characterize polyadenylation genome-wide in three SI-NETs and a reference sample. In the tumors, 16 genes showed significant changes of APA pattern, which lead to either the 3' truncation of mRNA coding regions or 3' untranslated regions. Among these, 11 genes had been previously associated with cancer, with 4 genes being known tumor suppressors: DCC, PDZD2, MAGI1, and DACT2. We validated the APA in three out of three cases with quantitative real-time-PCR. Our findings suggest that changes of APA pattern in these 16 genes could be involved in the tumorigenesis of SI-NETs. Furthermore, they also point to APA as a new target for both diagnostic and treatment of SI-NETs. The identified genes with APA specific to the SI-NETs could be further tested as diagnostic markers and drug targets for disease prevention and treatment.Entities:
Keywords: carcinoids; gene transcription; molecular biology; neuroendocrine tumors; polyadenylation
Year: 2014 PMID: 24782827 PMCID: PMC3995063 DOI: 10.3389/fendo.2014.00046
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Types of APA. UTR-APA: APA utilizing polyA sites located in the 3′ UTR of the last exon is called UTR-APA and results in mRNAs with the same coding region, but with different 3′ UTR length. CR-APA: APA utilizing polyA sites located in introns, or in the coding region of exons, is called CR-APA and results in mRNAs with 3′ truncated coding regions. Adapted from Ref. (53)
SI-NET biopsies.
| Identifier | Tissue of origin | Sex/age | Synaptophysin | Chromogranin | Serotonin | CD117 |
|---|---|---|---|---|---|---|
| NE MTT | Ileum | M/73 | + | + | + | − |
| NE CT1 | Ileum | F/66 | + | + | NA | NA |
| NE 2TC | Ileum | M/73 | + | + | + | − |
Read processing statistics.
| NE MTT | NE CT1 | NE 2TC | PIT | |
|---|---|---|---|---|
| Raw reads | 4895411 | 10878794 | 8859412 | 9773879 |
| Uniquely mapped reads (>21 nt) | 2012076 | 4465454 | 3675490 | 4027944 |
| Reads filtered after removing internal priming events | 1918905 | 4266418 | 3499253 | 3816258 |
| Clusters (including singletons) | 686450 | 1352151 | 1296130 | 1289606 |
| PolyA sites | 221147 | 398528 | 379890 | 385451 |
Figure 2Schematic representation of read processing and clustering.
Figure 3(A) Distribution of identified polyA sites across the genome for each of the samples analyzed. (B) Average number of reads per polyA site in different genomic regions.
Genes with UTR-APA specific to the SI-NETs.
| Gene | Function | Role in cancer | APA | Functional consequence |
|---|---|---|---|---|
| Subunit of the proteasome | Overexpressed in breast cancer ( | Increased usage of a proximal polyA site in the 3′UTR | Shortening of 3′UTR by 325 nt with loss of miRNA target sites for three miRNAs present in SI-NETs: hsa-mir-22*, hsa-mir-192*, and hsa-mir-1263 | |
| Negative regulator of the TGF-β/nodal signaling pathway | Tumor suppressor ( | Increased usage of two proximal polyA sites in the 3′UTR | Shortening of 3′UTR by up to 12113 nt without loss of miRNA target sites | |
| Transmembrane protein with unknown function | Unknown | Increased usage of two proximal polyA sites in the 3′UTR | Shortening of 3′UTR by up to 2848 nt with loss of miRNA target sites for 13 miRNAs present in SI-NETs: hsa-mir-1826, hsa-mir-338-5p, hsa-mir-552, hsa-mir-532-3p, hsa-mir-7-2*, hsa-mir-7-1*, hsa-mir-10b*, hsa-mir-140-3p, hsa-mir-193b*, hsa-mir-550*, hsa-mir-200c*, hsa-mir-17*, and hsa-mir-93* | |
| Membrane complement regulatory protein | Overexpressed and anti-apoptotic ( | Increased usage of two proximal polyA sites in the 3′UTR | Shortening of 3′UTR by up to 4707 nt with loss of miRNA target sites for one miRNA present in SI-NETs: hsa-mir-629 | |
| Pyrophosphate transport regulator | Amplified and suggested overexpressed ( | Increased usage of a proximal polyA site in the 3′UTR | Shortening of 3′UTR by 4879 nt with loss of miRNA target sites for eight miRNAs present in SI-NETs: hsa-mir-330-3p, hsa-mir-29b-2*, hsa-mir-1275, hsa-mir-625, hsa-mir-452, hsa-mir-628-3p, hsa-mir-30a*, and hsa-mir-30e* | |
| Role in iron–sulfur protein biogenesis | Interacts with tumor suppressor WT1 ( | Increased usage of two proximal polyA sites in the 3′UTR | Shortening of 3′UTR by up to 2581 nt with loss of miRNA target sites for nine miRNAs present in SI-NETs: hsa-mir-550*, hsa-mir-200c*, hsa-mir-214*, hsa-mir-423-5p, hsa-mir-660, hsa-mir-29b-1*, hsa-mir-1246, hsa-mir-7-1*, and hsa-mir-7-2* | |
| Splice factor | Overexpressed in breast cancer and anti-apoptotic ( | Increased usage of a proximal polyA site in the 3′UTR | Shortening of 3′UTR by 312 nt with loss of miRNA target sites for seven miRNAs present in SI-NETs: hsa-mir-338-5p, hsa-mir-628-3p, hsa-mir-409-3p, hsa-mir-183*, hsa-mir-330-3p, hsa-mir-7-1*, and hsa-mir-7-2* | |
| Mitochondrial ribosomal protein | Unknown | Increased usage of a proximal polyA site in the 3′UTR | Shortening of 3′UTR by 1888 nt with loss of miRNA target sites for 16 miRNAs present in SI-NETs: hsa-mir-671-5p, hsa-mir-193b*, hsa-mir-551b*, hsa-mir-338-5p, hsa-mir-30b*, hsa-mir-125b-2*, hsa-mir-330-3p, hsa-mir-7-1*, hsa-mir-7-2*, hsa-mir-188-5p, hsa-mir-769-5p, hsa-mir-324-3p, hsa-mir-552, hsa-mir-193a-5p, hsa-mir-501-5p, and hsa-mir-362-5p | |
| NADH dehydrogenase | Unknown | Increased usage of a proximal polyA site in the 3′UTR | Shortening of 3′UTR by 563 nt with loss of miRNA target sites for six miRNAs present in SI-NETs: hsa-mir-552, hsa-mir-21*, hsa-mir-664*, hsa-mir-505*, hsa-mir-550, and hsa-mir-500* |
Genes with CR-APA specific to the SI-NETs.
| Gene | Function | Role in cancer | APA compared | Functional consequence |
|---|---|---|---|---|
| Receptor for the axon guidance molecule nextrin | Tumor suppressor ( | Increased usage of a proximal polyA site located in intron 5 | Usage of this polyA site leads to expression of an mRNA lacking 24 exons in the 3′end, which translates into a highly C-terminally truncated DCC protein containing only 5 Ig-like domains and lacking both the nextrin binding domain, the transmembrane domain, and the intracellular domain. Thus, it lacks the parts responsible for the tumor suppressive functions ( | |
| PDZ domain-containing protein | Can be cleaved near its C-terminus to generate a secreted form sPDZD2 with tumor suppressive function ( | Increased usage of two proximal polyA sites located in intron 2 | Usage of these polyA sites leads to expression of an mRNA lacking 23 exons in the 3′end, which translates a highly C-terminally truncated PDZD2 protein, lacking the ability to form sPDZD2 and thus the tumor suppressive function ( | |
| Scaffolding protein localized at cell–cell contacts, containing PDZ domains | Tumor suppressive and anti-metastatic, through β-catenin recruitment to the cell membrane and thus inhibition of the Wnt/β-catenin signaling pathway ( | Increased usage of two proximal intronic polyA sites located in the intron 2 | Usage of these polyA sites leads to expression of an mRNA lacking 21 exons in the 3′end, which translates a highly C-terminally truncated MAGI1 protein, lacking all PDZ domains and thus the tumor suppressive function ( | |
| Zinc finger protein | Unknown | Increased usage of a proximal polyA site located in intron 5 | Usage of this polyA site leads to expression of an mRNA lacking five exons in the 3′end, which translates into a highly C-terminally truncated ZCWPW2 protein | |
| Transcriptional repressor | Overexpressed in cancer cell lines ( | Increased usage of a proximal polyA site located in the fifth last intron | Usage of this polyA site leads to the expression of an mRNA lacking five exons in the 3′end. The 3′-end of this mRNA isoform corresponds to the 3′-end of the 4.2-kB mRNA overexpressed in cancer cell lines ( | |
| Chaperone protein | Unknown | Increased usage of a proximal intronic polyA site located in intron 1 | Usage of this polyA site leads to the expression of an mRNA lacking five exons in the 3′end, giving rise to C-terminally truncated RIC3 protein | |
| Unknown | Frequently truncated in thyroid adenomas and the truncated allele is hypothesized to play a role in the thyroid tumorigenesis ( | Increased usage of a proximal polyA site located in the intron 22 | Usage of this polyA site leads to the expression of an mRNA lacking 16 exons in the 3′end, i.e., more than in the thyroid adenomas ( |
Expression ratio of (short isoform/long isoform) derived from DRS data.
| NE 2TC | 25 | 14 | 3.725490196 |
| NE CT1 | 156 | 15.66666667 | 2.173469388 |
| NE MTT | Inf | 36 | 3.25 |
| PIT | 0.128205128 | 0.652631579 | 0.735294118 |
Expression ratio of (short isoform/long isoform) derived from Q-RT-PCR data.
| NE 2TC | 3.853506079 | 0.026305316 | 25.55396049 |
| NE CT1 | 2.887782327 | 0.012957265 | 14.26667269 |
| NE MTT | 1.019851667 | 0.032658206 | 30.08928667 |
| PIT | 2.030313016 | 0.025800759 | 3.645085529 |
Expression ratio of (short isoform/long isoform) normalized to reference sample, derived from Q-RT-PCR data.
| NE 2TC | 1.897986 | 1.019556 | 7.010524 |
| NE CT1 | 1.422334 | 0.502205 | 3.913947 |
| NE MTT | 0.502313 | 1.265785 | 8.254755 |